In various aspects, the invention provides compositions of variable-length hydrophobically-modified polymers. These variable-length hydrophobes decorated along the hydrophilic polymer backbone provide advanced properties and allow for precise control over the behavior of the resulting amphiphilic polymer, including in aqueous solution. Such control allows for enhanced functionality of the amphiphilic polymer relative to standard single-length hydrophobe grafting designs, including for hemostasis.

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

The present invention relates to an apparatus for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using a woven fabric, a method for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using the apparatus, and a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric manufactured by the method, especially, a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric for use in a hemostatic agent or an anti-adhesive agent.

The present invention relates to an apparatus for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using a woven fabric, a method for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using the apparatus, and a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric manufactured by the method, especially, a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric for use in a hemostatic agent or an anti-adhesive agent.

The present invention relates to an apparatus for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using a woven fabric, a method for manufacturing a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric by using the apparatus, and a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric manufactured by the method, especially, a fibrous web, a fibrilla fiber aggregate, or a nonwoven fabric for use in a hemostatic agent or an anti-adhesive agent.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

The present invention is directed to a flowable hemostatic paste comprising a crosslinked carboxymethyl cellulose and at least one non-toxic dispersant. More specifically the present invention relates to a hemostatic paste containing citric acid cross-linked CMC, which is suspended or dispersed as a powder in a mixture of a first non-toxic glycerol-containing hygroscopic dispersant and a second non-toxic alcohol functionalized dispersant comprising propylene glycol or 1,3-butanediol.